Revenue of $19.0 million, compared to $16.7 millionGross loss of $(5.2) million compared to $(11.7) millionLoss ...

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target ...

Adjusted EBITDA totaled $ (21.1) million in the first quarter of fiscal 2025, compared to Adjusted EBITDA of $ (29.1) million in the first quarter of fiscal 2024. Please see the discussion of non-GAAP ...

Dragon Ball Z counts with many iconic villains in the manga, games, and anime. The likes of Freeza, Perfect Cell and Buu are ...

New poster to highlight preclinical data of CER-1236 in ovarian cancerSOUTH SAN FRANSCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CERo ...

NKGen Biotech, Inc. ("NKGen” or the "Company”) has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025; and ...

On paper, the Xiaomi 15 Ultra offers a lot of great specs. Powerful Leica-tuned cameras, including an absurd 200MP telephoto lens, a large battery, and all the performance of the new Snapdragon 8 ...

What is the immune system? The immune system works to keep germs and other foreign substances out of the body and destroy any that get in. It's made up of a complicated network of cells and organs. It ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies ...

"The real stars of this movie, however, are the entire team of actors, all with actual disabilities, who act and play the lights out under Harrelson's gifted coaching," before admitting ...

Hundreds of millions of years ago, there was only a single supercontinent known as Pangea. And millions of years in the future, there may be a new continent — because Africa is splitting. Indeed, ...

(NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that the Company’s Board of ...